In parallel, emerging CD123-directed CAR T-cell therapies, such as MB-102 (NCT04109482), have shown preclinical efficacy in KMT2A-r AML, offering a novel combinatorial approach with Menin inhibitors [76, 84, 85]. Here, MEN1 is linked to acute myeloid leukemia.